Director, Business Intelligence
Apellis Pharmaceuticals
Director, Business Intelligence
Apellis Pharmaceuticals
Develops complement inhibition therapies for diseases
Opportunity awaits those up to the challenge of developing transformative therapies across a broad range of debilitating diseases.
Summary:
We are seeking a talented and energetic Director, Business Intelligence (BI) – EMPAVELI who will play a key role in the commercialization of EMPAVELI in PNH. The Director will be accountable for partnering closely with U.S. commercial, and cross-functional teams to generate market-specific insights from sales and performance analytics and primary market research, to create integrated, actionable insights for cross-functional stakeholder groups across the organization. The ideal candidate must have significant experience working in a commercial insights and analytics position within a biotech or biopharma company, focusing on rare diseases (hematology a plus). The Director will report to the Senior Director, Business Intelligence & Commercial Operations – EMPAVELI, and is expected to drive market knowledge and insights that foster cross-functional action, shaping strategy and tactical execution for EMPAVELI in PNH in the US.Roles and Responsibilities:
Key Responsibilities
Qualifications
Employment
Work Arrangement:
HybridTravel Requirements:
Domestic retravel may be required in this role (up to 20%)Education:
Bachelor's DegreeBenefits and Perks:Apellis offers a comprehensive benefits package, inclusive flexible time off, summer and winter shutdowns, paid family leave and more!
Company Background:
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases.
For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Other Duties:
Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.
Develops complement inhibition therapies for diseases
Apellis Pharmaceuticals develops therapies that target the complement system, a part of the immune system involved in inflammation and disease. The company focuses on complement inhibition to treat rare and debilitating conditions with unmet medical needs. Its approach centers on therapies that precisely modulate the complement cascade to help patients. Apellis went public in 2017 to fund its research and development efforts, and in 2025 it formed a strategic partnership with Sobi to sell ex-US royalties on its drug Aspaveli for up to $300 million, providing capital and expanding global reach. Compared with competitors, Apellis pursues targeted complement modulation and leverages strategic partnerships and royalties to support its growth. The company's goal is to advance effective, targeted treatments that improve the lives of patients worldwide by addressing diseases driven by the complement system.
Explore more opportunities at Apellis Pharmaceuticals